{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-25-000213","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.540409+00:00","generated_at":"2026-05-17T21:41:34.056835+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vertex Q2 revenue $2.96B (+12% YoY); CSO Altshuler to retire Aug 2026; Bunnage to succeed","bullets":["Q2 revenue $2.96B (+12% YoY); GAAP net income $1.0B vs loss $3.6B last yr; non-GAAP net income $1.2B vs loss $3.3B","Reiterated FY25 revenue guidance $11.85-$12.0B; combined R&D/SG&A guidance unchanged","CSO David Altshuler to retire Aug 1, 2026; Mark Bunnage becomes CSO effective Feb 1, 2026 as planned transition","VX-993 Phase 2 acute pain study missed primary endpoint; Vertex not advancing it as monotherapy","CASGEVY: ~115 patients had first cell collection, 29 infused; JOURNAVX: >110,000 prescriptions filled"],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-25-000213","json":"https://secwatch.observer/filing/0000875320-25-000213.json","markdown":"https://secwatch.observer/filing/0000875320-25-000213.md","text":"https://secwatch.observer/filing/0000875320-25-000213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/0000875320-25-000213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/vrtx-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:41:34.056835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}